Prostate Cancer

Why we focus on Prostate Cancer

Prostate cancer is the most common cancer in Western men, accounting for over 250,000 deaths per year worldwide. Although about half of prostate cancer patients will die with the cancer rather than of it, prostate cancer is still the second leading cause of male cancer death. It is currently difficult to distinguish between latent and aggressive cancers, and once prostate cancer spreads, it is incurable.  Therefore, it is important to identify factors that influence both prostate cancer progression and the therapeutic response, and which could be used to develop biomarkers for tumour behaviour and potential targets for novel therapies.

What we do

  • Establish and maintain a male urogenital cancer tissue bank.
  • Identify critical genes in the development and progression of prostate cancer using a genome-wide analysis approach.
  • Identify biomarkers to predict aggressive prostate cancer.
  • Investigate the mechanism and consequence of genomic alterations in prostate cancer development.
  • Investigate the genetic and environmental factors associated with key genomic alterations in prostate cancer.
  • Develop experimental therapies based on specific genetic changes in cancer cells.
  • Investigate the potential of using gene therapy for prostate cancer treatment, including the application of adenovirus.
  • Investigate anti-tumour efficacy and mechanisms of co-inhibitors of androgen receptor activity in late stage prostate cancer.
  • Run clinical trials of optimised hormone therapy for prostate cancer, and alternative hormone and chemotherapy.

Key Publications

  • T Powles et al. MPDL3280A (Anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. 2014; Nature 515; 558–562
  • Yeste-Velasco et al.Identification of ZDHHC14 as a novel human tumour suppressor gene. J Pathol. 2014; 232(5):566-77
  • Ahmed et al. Focal salvage therapy for localized prostate cancer recurrence after external beam radiotherapy: A pilot study. Cancer. 2012. 118(17):4148-55
  • Adam et al. Synergistic and Selective Cancer Cell Killing Mediated by the Oncolytic Adenoviral Mutant Ad?? and Dietary Phytochemicals in Prostate Cancer Models. Hum Gene Ther. 2012 Sep;23(9):1003-15
  • Wong et al. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11. Mol Ther. 2012 20(2):306-16
  • Kote-Jarai et al. Seven novel prostate cancer susceptibility loci identified by a mutli-stage genome-wide association study. Nat Genet 2011; 43(8): 785-91 

Who does the research

→ Click here for BCI researchers working on prostate cancer

Major Funders

  • Orchid
  • Association for International Cancer Research
  • Cancer Research UK
  • GlaxoSmithKline
  • MRC
This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.